Results 271 to 280 of about 5,061,790 (379)

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

Angiotensin II Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation Through an Angiotensin II Type I Receptor–Dependent Mechanism

HYPERTENSION, 2014
Matthew R. Deshotels, Huijing Xia, S. Sriramula, E. Lazartigues, C. Filipeanu   +4 more
semanticscholar   +1 more source

Direct Vascular Effects of Angiotensin II (A Systematic Short Review). [PDF]

Int J Mol Sci
Nádasy GL, Balla A, Dörnyei G, Hunyady L, Szekeres M.   +4 more
europepmc   +1 more source

Angiotensin II receptors in adrenal cortex and uterus. Binding and activation properties of angiotensin analogues.

, 1979
A M Capponi, Kevin Catt
openalex   +1 more source

Response of aldosterone and blood pressure to angiotensin II infusion in anephric man. Effect of sodium deprivation. [PDF]

, 1976
J Deheneffe, V. Cuesta, J. D. Briggs, J. J. Brown, R. Fräser, A. F. Lever, J. J. Morton, Iris Robertson, M. Tree   +8 more
openalex   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Circulating Angiotensin II Gains Access to the Hypothalamus and Brain Stem During Hypertension via Breakdown of the Blood–Brain Barrier

HYPERTENSION, 2014
V. Biancardi, S. Son, Sahra Ahmadi, J. Filosa, J. Stern   +4 more
semanticscholar   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

INFUSION OF ANGIOTENSIN-II ANALOGUE IN TWO PATIENTS WITH UNILATERAL RENOVASCULAR HYPERTENSION [PDF]

, 1974
A. J. M. Donker, Frans H. H. Leenen
openalex   +1 more source

CD148 agonistic antibody alleviates renal injury induced by chronic angiotensin II infusion in mice. [PDF]

BMC Nephrol
Takahashi K, Yu A, Otsuka T, Pasic L, Narui C, He L, Ellinger P, Grundmann M, Harris RC, Takahashi T.   +9 more
europepmc   +1 more source